Omega-3 in antiarrhythmic therapy : pros position

Area of Science:

• Cardiology
• Nutraceuticals
• Pharmacology

Background:

• Omega-3 (n-3 polyunsaturated fatty acids) has shown efficacy in reducing global mortality and is indicated for preventing sudden death post-myocardial infarction.
• Clinical studies investigating the antiarrhythmic effects of omega-3 have yielded contradictory results, potentially due to variations in patient populations and dosages.
• Despite conflicting findings, specific nutraceutical formulations containing omega-3 have demonstrated antiarrhythmic properties in certain patient groups.

Purpose of the Study:

• To evaluate the antiarrhythmic potential of omega-3 fatty acids.
• To investigate the efficacy of a specific omega-3 nutraceutical (Ritmonutra®) in reducing arrhythmias.
• To assess the safety and impact of omega-3 on cardiac function during arrhythmia treatment.

Main Methods:

• Studies involved patients with post-ischaemic dilatative cardiomyopathy and implantable cardioverter defibrillators (ICDs).
• A nutraceutical combination containing omega-3 (Ritmonutra®) was administered to assess its effect on arrhythmias.
• Holter ECG monitoring was used to evaluate antiarrhythmic effects in patients with essential hypertension and a history of arrhythmia.

Main Results:

• Ritmonutra® significantly reduced premature ventricular contractions (46%), premature supraventricular contractions (54.2%), supraventricular tachycardia runs (48%), and sustained ventricular tachycardia (33%) in cardiomyopathy patients.
• In hypertensive patients, omega-3 treatment significantly decreased both ventricular and supraventricular arrhythmias compared to placebo.
• No adverse effects on left ventricle function, heart rate, intra-cardiac conduction, or contractility were observed with omega-3 treatment.

Conclusions:

• Omega-3 fatty acids, particularly in specific nutraceutical formulations like Ritmonutra®, demonstrate significant antiarrhythmic effects.
• These findings suggest omega-3s can be a valuable therapeutic option for managing both ventricular and supraventricular arrhythmias.
• Unlike some traditional antiarrhythmics, omega-3s do not negatively impact myocardial contractility, offering a favorable safety profile for arrhythmia treatment.